InSightec's ExAblate fibroid therapy gets Japanese approval
This article was originally published in Clinica
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved InSightec's ExAblate system for the treatment of uterine fibroids. The device combines magnetic resonance imaging (MRI) to visualise the fibroids and high-intensity focused ultrasound to thermally ablate them. Fibroids are benign tumours that can cause painful and heavy menstrual bleeding, pain during sexual intercourse, and urinary frequency and urgency. Symptomatic fibroids affect around 25% of Japanese women. Other treatments are either less effective, such as hormone therapy, or involve invasive surgery including hysterectomy. Tirat Carmel, Israel-based InSightec CE marked the system for sale in Europe in 2002, and it received US FDA approval in 2004 for uterine fibroids. It is also CE marked for pain palliation of bone metastases. GE Healthcare will distribute the product in Japan.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.